CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update
Globe Newswire•05/11/2026•16:15 ET
0
Key Highlights
- ➤$348.0 million cash, equivalents and investments; runway expected into second half of 2028
- ➤Varseta-M received FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer
- ➤January 2027 Phase 1 Varseta-M mCRC monotherapy data update expected
- ➤Varseta-M and bevacizumab Phase 1 combination study ongoing; initial data anticipated in 1H 2027
- ➤Q3 revenue $1.7 million versus $6.0 million year-over-year; operating expenses rose to $25.2 million
Expert Statements
Sean McCarthy, Chairman and CEO of CytomX Therapeutics
“Varseta-M is a first-in-class EpCAM-directed antibody drug conjugate with a topoisomerase-1 inhibitor payload, intentionally designed to improve the standard of care for patients with colorectal and other cancers. At CytomX, we are highly focused on rapidly advancing monotherapy Varseta-M towards a first registrational study in colorectal cancer”
Sean McCarthy, Chairman and CEO of CytomX Therapeutics
“Additionally, the Varseta-M development program continues to broaden, including an ongoing combination study with bevacizumab in mCRC and the initiation of Phase 1 expansion cohorts in gastric and gastroesophageal junction cancer, EpCAM-selected pancreatic ductal adenocarcinoma, and EpCAM-selected biliary tract cancer. Our integrated strategy is intended to urgently advance Varseta-M for the maximum benefit of cancer patients.”
- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer -
- Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 -
Get started
Create a free account to read the full story.